White Paper

Lenvima is an oral tyrosine kinase inhibitor approved in multiple indications, including differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.

We offer two polymorphic forms:

1) Lenvatinib Mesylate MIBK solvate
2) Lenvatinib Mesylate Form-C.

A MIBK solvate is a novel form that offers in several markets an early launch advantage over the polymorph patent.

The US DMF has been filed for both forms:

* Lenvatinib Mesylate MIBK solvate in June 2018.
* Lenvatinib Mesylate Form-C anhydrous in June 2021.

We are well-positioned to meet the global demand for Lenvatinib API, with the ability to scale-up to meet commercial requirements whenever needed. Want to know more about our API offerings, please fill in the contact details below.